Dallas, Texas 03/25/2014 (FINANCIALSTRENDS) – Neuralstem, Inc (NYSEMKT:CUR) announced that their final results from its Phase I safety- trial using the NSI-566 spinal-cord stem cells for treating amyotrophic lateral–sclerosis have been published in their peer-reviewed journal- the “Annals of Neurology”. In the “Intraspinal Neural StemCell Transplantation in Amyotrophic-Lateral Sclerosis: Phase-I Trial Outcomes,” the results were all updated from the Phase I interim data that had been reported earlier. It would include the data from the last 6 patients in this trial. These 6 patients were the 1st cervical stem cell transplants.
Three of the patients were also the 1st spines, in both – lumbar & cervical regions. These results showed that the NSI-566 human spinal-cord stem cells can now be safely-transplanted in the lumbar 7 the cervical-spinal cord to receive the to be transplanted along this in the length of the segments. These did not accelerate the disease progression, and also warrant further-study on the dosing as well as in therapeutic efficacy. In addition, the researchers were also able to identify the potential and therapeutic windows, that suggested that even more injections, and other multiple injections, are much better and mighty increase both its length as well as the magnitude of all the potential benefits.
This is now consistent with its hypothesized neuroprotective and the mechanism-of-action for this particular cell therapy. Since concluding the Phase I, this trial has now progressed to the Phase II at 3 centers, – Emory University Hospital in Atlanta, in Georgia, The ALS Clinic at University of Michigan Health System, located in Ann Arbor, in Michigan, and the Massachusetts General Hospital located in Boston, in Massachusetts, that treated its 1st patient in Feb. Treatment of 3 of the 5, Phase2 cohorts has now been completed. Although this was the Phase One trial, & functional outcome-data were collected for this purpose of assessing the safety, they performed the secondary analyses of these data.